

Supporting conversations between women with epilepsy and their PRIMARY CARE TEAM

Checklist for appointments with your **PRIMARY CARE TEAM** (GP and Practice Nurse)

en actice Nurse)

OVERVIEW OF WHAT THIS CHECKLIST COVERS:

children exposed to Valproate during pregnancy. You should share any plans for pregnancy with a healthcare

professional at the earliest convenience.

OUTSIDE OF CONCEPTION	FAMILY PLAININING			DURING PREGNANCY	
☐ Fertility	Referral			Referral to epilepsy specialist and maternity care teams	
☐ Contraception	☐ Planning ahead			☐ Pregnancy sickness	
Folic acid	Preconception counselling		elling	Changes in seizure frequency	
☐ Valproate and Topiramate				☐ Blood tests	
1. Outside of conception		2. F	amily planning		
Epilepsy itself is not a reason for infertility but you need to consider issues such as medication, seizure safety and potential for seizures when planning to start a family requires a few more considerations (i.e., review of medications, seizure safety and potential for seizures).			Family planning should be discussed at the If you are planning to start a family, you sho to the epilepsy specialist team for a medical Be cautious that assumptions may be made if a woman is not married) about whether so	ng to start a family, you should be referred specialist team for a medication review. cassumptions may be made (for example, t married) about whether someone is	
Contraception:			•	tarting a family. No matter the stage	
The potential for becoming pregnant needs for contraception depending o should be assessed.			thinking about s It should be high	bu should contact the epilepsy team if you are about starting a family in the next 12 months. I be highlighted that starting a family can take	
 Contraception options and information interact with epilepsy medication show available to you. This is because contractiveness may be reduced by som Medications (ASMs). Further informat the Epilepsy Ireland website. Folic acid should be prescribed to wo 	uld be made raception e Anti-Seizure ion can be found via		time (sometimes 12 months or more), especially if ASMs need to be changed. You do not need to be planning a pregnancy in the next year to get this information and it is advised to plan ahead as much as possible. Note: changes to ASMs could impact your seizure frequency, which could affect your lifestyle i.e., driving or spending long periods alone. Although it is not necessary it may be useful to inform workplaces or friends/family. Preconception counselling should be offered, or given if you ask for it. In this counselling, details about the risks		
potential. The specific dosage and us determined by your epilepsy specialis	age will be			counselling should be offered, or given if	
It is no longer advised to prescribe Va Topiramate for women of childbearing other treatments are ineffective or no more about Valproate via the HPRA w	g potential, unless t tolerated. Find out		(including safety SUDEP - Sudder	advice and cautioned about the risk of Unexpected Death in Epilepsy) and egnancy with epilepsy will be explained.	
For those whom Valproate or Topiran effective treatment, advice should be use of effective contraception and the malformations and neurodevelopmen	provided on the e risks of congenital				

3. During pregnancy	4. Key questions to consider by women with epilepsy		
Immediately after a positive pregnancy test:	during these stages		
You should contact the GP and epilepsy specialist team to plan the next steps and appropriate referrals onto the maternity care team. Epilepsy medication should not be stopped.	Can I still have children? Epilepsy itself is not a reason for infertility and consideration to start a family are still appropriate, but this process require a few more considerations (i.e., review of medications, seizure safety and potential for seizures).		
Should you experience pregnancy sickness; this could interfere with medication adherence. Get in contact with the GP or the epilepsy specialist and maternity care team should this happen to seek further advice. For more general information on pregnancy sickness, please see	What type of contraception is the most suitable for me? Suitable contraception options are dependent on the type of antiseizure medications. For more information, please see the Epilepsy Ireland website. When should I consider information on family planning? At your earliest convenience. Even if you are not planning a family now, medication adjustments can take up to and beyond 12 months of planning, so it is best to start conversations earlier to be prepared.		
the <u>HSE website</u> . Seizure patterns can change during pregnancy. As a general rule, one-third of women may have fewer seizures, one-third may stay the same, and one-third may have more seizures. Any changes in seizure frequency or			
concerns should be checked by the epilepsy specialist and maternity care teams. Throughout the pregnancy there should be regular blood tests taken by the primary care team. This is for drug levels to be assessed by the epilepsy specialist team. Depending on results, the epilepsy specialist team may alter your medications. Medication levels can change at a	What do I need to consider during family planning? Each medication's safety should be considered, and information about it should be given to you. Any changes to medication and how they might affect seizure frequency and safety during pregnancy should also be explained. This checklist can help with preparing what to think about and ask.		
 quicker pace during pregnancy. If there are any concerns that seizure frequency is changing, contact the epilepsy specialist and maternity care teams. The team should encourage preconception advice be sought before planning another pregnancy. 	What are my considerations during pregnancy? Managing epilepsy during pregnancy may require additional blood tests, and changes in medication or doses and maintaining a healthy lifestyle (e.g., good sleep hygiene) to reduce seizure risks. You must not stop taking your epilepsy medication during pregnancy.		
Your notes			

This research was funded by the Health Research Board APA-2022-014, with co-funding from Epilepsy Ireland and the HSE National Women and Infants Health Programme







